BCL2 and cancer: For example, a small molecule, named ABT-737, was issued as a potential inhibitor of BCL-2 and BCL-XL, which occupies their BH3-binding domain and further triggers apoptosis in diversified cancer types (Tse et al., 2008; Soderquist and Eastman, 2016).